YELLOWGrowth Hormone Axis

4X Blend (GHRP-2/Tesamorelin/MGF/Ipamorelin)

4X Blend (GHRP-2 / Tesamorelin / MGF / Ipamorelin)

Research compound1 SKU available
IpamorelinIpamorelin

Blend components — PubChem

Research Hub — Aggregated Studies

MedTech Research Group aggregates published research from peer-reviewed journals, clinical trials, and academic institutions. We do not conduct original research. All studies cited below are the work of their respective authors and institutions. Sources are linked for verification.

This product is designated FOR RESEARCH USE ONLY (RUO). These compounds have not been approved or cleared under 21 U.S.C. § 505 and have not been evaluated by the FDA for safety, efficacy, or labeling for clinical, diagnostic, or therapeutic use in humans or animals.

MedTech Research Group will only fulfill orders to qualified researchers affiliated with accredited academic institutions, licensed research facilities, or organizations with active IRB/IACUC oversight.

Purchaser Restrictions

  • Purchaser must be a qualified researcher at an accredited institution or licensed research facility
  • This product may not be sold or redistributed to individual consumers, wellness clinics, health food stores, or retail establishments
  • Not intended for human or animal consumption, diagnostic use, or therapeutic application
  • Institutional affiliation and research purpose will be verified prior to order fulfillment

Distribution is limited to qualified research use in compliance with applicable federal and state law. These products bear the "For Research Use Only" designation per FDA labeling requirements (minimum 10 pt. font). Ref: 21 U.S.C. § 505; FD&C Act § 201(p) (unapproved new drug definition).

Compound Overview
Risk TierYELLOW
CategoryGrowth Hormone Axis
SubcategoryMulti-Peptide GH / Recovery Combination
Pharmacological ClassMulti-Peptide Blend
SubclassGHRH Analog + GHS + Growth Factor Combination
Molecular TypeBlend of four synthetic peptides targeting multiple GH and growth pathways
OriginSynthetic proprietary blend (Standard sourcing)
Regulatory StatusResearch Use Only. Not FDA-approved as a combination. Individual components have varying levels of published research.
Route of AdministrationSubcutaneous injection
ReconstitutionLyophilized powder; reconstitute with bacteriostatic water
StorageRefrigerate (2-8°C)
Detailed Research

Description

The 4X Blend is a proprietary multi-peptide formulation combining four growth-related peptides that target complementary receptor systems and growth pathways. GHRP-2 (Growth Hormone-Releasing Peptide-2) is a hexapeptide GH secretagogue with intermediate selectivity — more selective than GHRP-6 but less selective than ipamorelin. It activates the ghrelin receptor (GHS-R1a) to stimulate GH release with moderate appetite stimulation and mild cortisol/prolactin effects. Tesamorelin is the FDA-approved full-length GHRH analog that activates the complementary GHRH receptor pathway (cAMP/PKA) on pituitary somatotrophs. Ipamorelin provides additional selective GHS-R1a activation without cortisol or prolactin concerns. MGF (Mechano Growth Factor, a splice variant of IGF-1, specifically the IGF-1Ec isoform) is a growth factor produced locally in muscle tissue in response to mechanical stress (exercise), promoting satellite cell activation and muscle repair.

The combination creates a multi-pathway approach: two independent pituitary GH secretagogue pathways (GHRH-R via tesamorelin + GHS-R1a via GHRP-2 and ipamorelin) plus direct peripheral tissue repair stimulation (MGF). The inclusion of both GHRP-2 and ipamorelin at the GHS-R1a provides a combined dose while leveraging ipamorelin's selectivity to balance GHRP-2's broader effects. This is a more aggressive GH-axis protocol than the standard CJC-1295/ipamorelin blend, with the addition of the peripheral growth factor component.

Clinical Context

The 4X Blend is positioned as a comprehensive GH-axis and recovery formulation from the Standard sourcing tier ($78.00). It targets users who want a multi-pathway approach combining central GH release with peripheral tissue repair signaling. The inclusion of MGF adds a direct tissue-level growth factor that does not depend on pituitary function. This blend is more complex and aggressive than the CJC-1295/Ipamorelin blend and is suitable for research protocols requiring multi-pathway stimulation.

Research Applications
Multi-pathway GH axis optimization
Muscle recovery and repair research
Body composition studies (lean mass gain, fat reduction)
Satellite cell activation and muscle regeneration studies
Post-exercise recovery protocols
Comprehensive anti-aging research protocols
Clinician Notes
Important Notes for Clinicians
  • Four-peptide blend is more complex than dual combinations — monitor for cumulative effects
  • GHRP-2 will produce mild appetite stimulation and modest cortisol/prolactin elevation (less than GHRP-6, more than ipamorelin)
  • MGF (500mcg) acts peripherally — does not require pituitary function but has a very short half-life (minutes); the lyophilized blend format helps preserve stability
  • Administer on an empty stomach for optimal pituitary GH release from the GHRH/GHS components
  • Standard sourcing (YPB.100) — different supplier tier than the Premier PLDS products
  • More aggressive protocol than CJC-1295/Ipamorelin — recommended for experienced researchers

Published Research

Published Research & Clinical Data

Peer-reviewed studies and clinical trial data related to 4X Blend (GHRP-2/Tesamorelin/MGF/Ipamorelin)

All research below is conducted by independent institutions. MedTech Research Group provides these references for informational purposes only.

Research citations are being compiled for this compound.

Check back soon — our team is curating peer-reviewed sources.